India Drug-Pricing Agency Tries New Tactic To Collect Overcharges
This article was originally published in PharmAsia News
India's drug-pricing authority has stepped up its efforts to get pharmaceuticals to pay the fines assessed them for charging too much. The National Pharmaceutical Pricing Authority is developing new guidelines that allow local government authorities to collect fines from drug makers in the areas where they actually have assets. The practice has been to refer cases to district authorities on a case-by-case basis, but the new NPPA guidelines strengthen the government's ability to collect the assessments. The NPPA already has used the new method to collect on overcharges in five cases. (Click here for more
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.